Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Inserra

Rheumatology Colorado Springs, CO Medical Doctor

NPI 1831610666 CMS profile 7233115

595 Chapel Hills Dr Ste 201, Colorado Springs, CO 80920

Open in the dashboard

General payments

$5,438

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Inserra of Colorado Springs, CO is reported in the CMS Open Payments database as having received $5,438 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,203 134
2024 General $1,992 105
2023 General $183 7
2019 General $60 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Inserra
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Christopher Inserra were reported at $3,203. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Christopher Inserra Rheumatology median Middle half National median
2019 $60 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $0 $627 $125–$2,303 $149
2023 $183 $741 $145–$2,524 $160
2024 $1,992 $830 $166–$2,660 $164
2025 $3,203 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,151 125 payments
  2. Amgen Inc. $1,243 38 payments
  3. UCB, Inc. $493 19 payments
  4. Janssen Biotech, Inc. $383 9 payments
  5. Pfizer Inc. $278 19 payments
  6. AstraZeneca Pharmaceuticals LP $264 11 payments
  7. Novartis Pharmaceuticals Corporation $105 6 payments
  8. Sobi, Inc $86 3 payments
  9. GlaxoSmithKline, LLC. $82 3 payments
  10. Sandoz Inc. $52 2 payments
  11. Other $301 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,127 244 payments
  2. Consulting Fee $175 1 payment
  3. Education $136 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,512 93 payments
  2. KRYSTEXXA $428 11 payments
  3. SKYRIZI Immunology $392 21 payments
  4. TREMFYA $383 9 payments
  5. Bimzelx $366 11 payments
  6. TAVNEOS $362 11 payments
  7. SAPHNELO $264 11 payments
  8. SKYRIZI Immunology $247 11 payments
  9. Prolia $206 5 payments
  10. XELJANZ $167 11 payments
  11. Other $1,212 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

443

Median for Rheumatology: 1,511

Drug cost

$211,906

Median for Rheumatology: $1,139,948

Branded share of claims

40.6%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 17 $128,650
Benlysta Belimumab Brand 14 $75,252
Methotrexate Methotrexate Sodium Brand 124 $3,431
Hydroxychloroquine Sulfate Generic 84 $3,092
Prednisone Generic 93 $644
Allopurinol Generic 27 $213
Methotrexate Sodium Methotrexate Sodium/Pf Brand 13 $195
Folic Acid Generic 31 $190
Alendronate Sodium Generic 28 $170
Insulin Syringe Syringe And Needle,insulin,1ml Brand 12 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$352,211

Of which drugs: $294,845

Medicare patients

164

Average age 73

Services billed

35,786

120 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 59%
Osteoporosis 37%
Depression 24%
Chronic kidney disease 22%
Ischemic heart disease 17%
Diabetes 15%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tocilizumab, 1 mg J3262 Office 12 16,250 $76,151
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 11 11,600 $42,309
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 132 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $601
$601 — —
SKYRIZI
  • AbbVie, Inc. $247
$247 — —
TAVNEOS
  • Amgen Inc. $105
$105 — —
Enbrel
  • Amgen Inc. $102
$102 17 —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record